MedTrace Logo

Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection

NCT04244084 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2022-05-17

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy and safety of ММН-407 in treatment of acute respiratory viral infection (ARVI).

Conditions

  • Viral Respiratory Infection

Interventions

DRUG

MMH-407

Oral use.

DRUG

Placebo

Oral use.

Sponsors & Collaborators

  • Materia Medica Holding

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-08
Primary Completion
2020-04-09
Completion
2020-04-09

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04244084 on ClinicalTrials.gov